MTOR and tuberous sclerosis: Although mTOR inhibitors have the potential to treat the entire spectrum of manifestations associated with TSC, there are a number of outstanding clinical issues surrounding the use of these targeted agents, including when mTOR inhibitor therapy should be initiated and how to best utilize these agents to for the treatment of specific TSC-associated manifestations [77].